Form D · Biotechnology
CARDIODX INC
Redwood City, CA · CIK 0001304909
Offering snapshot reported Jan 18, 2017 · SEC filing
- Reported sold
- $18.1M Offering amount: $41.8M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 5, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 18, 2017 | Initial | $18,125,400 | No comparison | 7 | SEC filing |
| Feb 22, 2016 | Amendment | $12,369,483 | $7,369,475vs Jun 30, 2015 | 15 | SEC filing |
| Jun 30, 2015 | Initial | $5,000,008 | No comparison | 13 | SEC filing |
| Jul 24, 2014 | Initial | $20,983,348 | No comparison | 14 | SEC filing |
| Aug 31, 2012 | Initial | $30,509,397 | No comparison | 28 | SEC filing |
| Mar 2, 2011 | Initial | $57,491,448 | No comparison | 17 | SEC filing |
| May 14, 2010 | Initial | $34,564,513 | No comparison | 16 | SEC filing |
| Oct 15, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jul 17, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-278640
Sale and issuance of (i) Series 1-A Preferred Stock, (ii) Series 1-B Preferred Stock, and (iii) Common Stock issuable upon conversion of Series 1-A Preferred Stock and Series 1-B Preferred Stock.
Source: Form D, filed Jan 18, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Brook H. Byers | Director |
| Gwen R. Carscadden | Executive |
| Fred Cohen | Director |
| Susan Daniels | Executive |
| Patrick G. Enright | Director |
| William Ericson | Director |
| Michael Goldberg | Director |
| Melinda Griffith | Executive |
| Andrew L. Guggenhime | Director |
| Jeff Heer | Executive |
| Tim Henn | Executive |
| Hongjie Hu | Director |
| Deborah L. Kilpatrick | Executive |
| Louis G. Lange | Director |
| David L. Levison | Director |
| Khushro F. Mehta | Director, Executive |
| Mark Monane | Executive |
| Arthur M. Pappas | Director |
| Amy Paye | Executive |
| Steven Rosenberg | Executive |
| Douglas T. Ross | Executive |
| Ajit Singh | Director |
| Risa Stack | Director |
| James R. Tobin | Director |
| Rafael Torres | Director |
| Mark Weeks | Executive |
| Robert F. Werner | Executive |
| Duane Williams | Executive |
| Mark .R. Willig | Executive |
| Jim Wingrove | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
600 Saginaw Dr.
Redwood City, CA, 94063
Redwood City, CA, 94063